A lawsuit filed by HDT Bio Corp against Pune-based Emcure Pharmaceuticals has been dismissed by a U.S. court. The Federal court in Seattle, Washington, rejected HDT’s lawsuit against Emcure related to Covid-19 vaccine technology.
A lawsuit initiated by HDT Bio Corp against Emcure Pharmaceuticals, based in Pune, has been dismissed by a U.S. court. The federal court in Seattle, Washington, has rejected HDT’s legal action against Emcure concerning Covid-19 vaccine technology.
In the lawsuit, HDT included Emcure as a party, claiming non-payment of royalties and seeking compensation of at least USD 950 million.
Upon inquiry, a spokesperson for the company stated, “The court’s decision supports and validates our position.” Emcure argued in court that the lawsuit was baseless and initiated by HDT to offset its own business inadequacies.
HDT Bio claimed that the Pune-based company had unlawfully appropriated its vaccine technology, which HDT had licensed to Gennova for production and distribution in India.
